SUTRO BIOPHARMA, INC. Net Income
SUTRO BIOPHARMA, INC. (STRO) reported Net Income of -$38.53 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-12
- SUTRO BIOPHARMA, INC. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$38.53M.
- SUTRO BIOPHARMA, INC. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$38.48M.
- SUTRO BIOPHARMA, INC. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$46.68M.
- SUTRO BIOPHARMA, INC. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$56.86M.
- SUTRO BIOPHARMA, INC. net income (loss) attributable to parent for fiscal 2022 was -$119.20M.
- SUTRO BIOPHARMA, INC. net income (loss) attributable to parent for fiscal 2021 was -$105.54M.
- SUTRO BIOPHARMA, INC. net income (loss) attributable to parent for fiscal 2020 was -$32.13M.
- SUTRO BIOPHARMA, INC. net income (loss) attributable to parent for fiscal 2019 was -$119.20M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$38.53M 10-Q · filed 2026-08-12 | -$77.02M 10-Q · filed 2026-08-12 | -$123.69M derived: sum of 3 quarters · filed 2026-08-12 | -$180.55M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | -$38.48M 10-Q · filed 2026-08-12 | -$85.16M derived: sum of 2 quarters · filed 2026-08-12 | -$142.02M derived: sum of 3 quarters · filed 2026-08-12 | -$153.52M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | -$46.68M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-22 | -$103.53M derived: sum of 2 quarters · filed 2026-04-22 | -$115.03M derived: sum of 3 quarters · filed 2026-08-12 | -$191.00M DEF 14A · filed 2026-04-22 | -$191.09M 10-K · filed 2026-03-23 |
| 2025-09-30 | -$56.86M 10-Q · filed 2025-11-06 | -$68.36M derived: sum of 2 quarters · filed 2026-08-12 | -$144.32M 10-Q · filed 2025-11-06 | -$216.31M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | -$11.50M 10-Q · filed 2026-08-12 | -$87.47M 10-Q · filed 2026-08-12 | -$159.45M derived: sum of 3 quarters · filed 2026-08-12 | -$208.24M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-03-31 | -$75.97M 10-Q · filed 2026-08-12 | -$147.95M derived: sum of 2 quarters · filed 2026-08-12 | -$196.74M derived: sum of 3 quarters · filed 2026-08-12 | -$244.75M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2024-12-31 | -$71.98M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-22 | -$120.77M derived: sum of 2 quarters · filed 2026-04-22 | -$168.79M derived: sum of 3 quarters · filed 2026-04-22 | -$227.00M DEF 14A · filed 2026-04-22 | -$227.46M 10-K · filed 2025-03-13 |
| 2024-09-30 | -$48.79M 10-Q · filed 2025-11-06 | -$96.81M derived: sum of 2 quarters · filed 2025-11-06 | -$155.02M 10-Q · filed 2025-11-06 | -$124.16M derived: sum of 4 quarters · filed 2026-04-22 | |
| 2024-06-30 | -$48.02M 10-Q · filed 2025-11-06 | -$106.23M 10-Q · filed 2025-08-07 | -$75.37M derived: sum of 3 quarters · filed 2026-04-22 | -$124.66M derived: sum of 4 quarters · filed 2026-04-22 | |
| 2024-03-31 | -$58.21M 10-Q · filed 2025-11-06 | -$27.36M derived: sum of 2 quarters · filed 2026-04-22 | -$76.64M derived: sum of 3 quarters · filed 2026-04-22 | -$115.16M derived: sum of 4 quarters · filed 2026-04-22 | |
| 2023-12-31 | $30.86M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-22 | -$18.43M derived: sum of 2 quarters · filed 2026-04-22 | -$56.95M derived: sum of 3 quarters · filed 2026-04-22 | -$107.00M DEF 14A · filed 2026-04-22 | -$106.79M 10-K · filed 2024-03-25 |
| 2023-09-30 | -$49.28M 10-Q · filed 2024-11-13 | -$87.81M derived: sum of 2 quarters · filed 2024-11-13 | -$137.86M 10-Q · filed 2024-11-13 | -$172.45M derived: sum of 4 quarters · filed 2025-03-13 | |
| 2023-06-30 | -$38.52M 10-Q · filed 2024-11-13 | -$88.57M 10-Q · filed 2024-08-13 | -$123.17M derived: sum of 3 quarters · filed 2025-03-13 | -$142.66M derived: sum of 4 quarters · filed 2025-03-13 | |
| 2023-03-31 | -$50.05M 10-Q · filed 2024-11-13 | -$84.64M derived: sum of 2 quarters · filed 2025-03-13 | -$104.13M derived: sum of 3 quarters · filed 2025-03-13 | -$130.14M derived: sum of 4 quarters · filed 2025-03-13 | |
| 2022-12-31 | -$34.59M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$54.08M derived: sum of 2 quarters · filed 2025-03-13 | -$80.09M derived: sum of 3 quarters · filed 2025-03-13 | -$119.20M 10-K · filed 2025-03-13 | |
| 2022-09-30 | -$19.49M 10-Q · filed 2023-11-13 | -$45.50M derived: sum of 2 quarters · filed 2023-11-13 | -$84.61M 10-Q · filed 2023-11-13 | -$122.73M derived: sum of 4 quarters · filed 2024-03-25 | |
| 2022-06-30 | -$26.01M 10-Q · filed 2023-11-13 | -$65.12M 10-Q · filed 2023-08-10 | -$103.25M derived: sum of 3 quarters · filed 2024-03-25 | -$134.15M derived: sum of 4 quarters · filed 2024-03-25 | |
| 2022-03-31 | -$39.11M 10-Q · filed 2023-11-13 | -$77.23M derived: sum of 2 quarters · filed 2024-03-25 | -$108.14M derived: sum of 3 quarters · filed 2024-03-25 | -$114.29M derived: sum of 4 quarters · filed 2024-03-25 | |
| 2021-12-31 | -$38.13M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | -$69.03M derived: sum of 2 quarters · filed 2024-03-25 | -$75.18M derived: sum of 3 quarters · filed 2024-03-25 | -$105.54M 10-K · filed 2024-03-25 | |
| 2021-09-30 | -$30.90M 10-Q · filed 2022-11-08 | -$37.05M derived: sum of 2 quarters · filed 2022-11-08 | -$67.41M 10-Q · filed 2022-11-08 | -$126.96M derived: sum of 4 quarters · filed 2022-11-08 | |
| 2021-06-30 | -$6.15M 10-Q · filed 2022-11-08 | -$36.51M 10-Q · filed 2022-08-08 | -$96.06M derived: sum of 3 quarters · filed 2022-11-08 | -$78.92M derived: sum of 4 quarters · filed 2022-11-08 | |
| 2021-03-31 | -$30.36M 10-Q · filed 2022-11-08 | -$89.90M derived: sum of 2 quarters · filed 2022-11-08 | -$72.76M derived: sum of 3 quarters · filed 2022-11-08 | -$42.89M derived: sum of 4 quarters · filed 2022-11-08 | |
| 2020-12-31 | -$59.54M 10-K · filed 2021-03-18 | -$42.41M derived: sum of 2 quarters · filed 2021-11-10 | -$12.53M derived: sum of 3 quarters · filed 2021-11-10 | -$32.13M 10-K · filed 2023-03-30 | |
| 2020-09-30 | $17.14M 10-Q · filed 2021-11-10 | $47.01M derived: sum of 2 quarters · filed 2021-11-10 | $27.42M 10-Q · filed 2021-11-10 | $12.63M derived: sum of 4 quarters · filed 2021-11-10 | |
| 2020-06-30 | $29.87M 10-Q · filed 2021-11-10 | $10.28M 10-Q · filed 2021-08-09 | -$4.51M derived: sum of 3 quarters · filed 2021-11-10 | -$17.42M derived: sum of 4 quarters · filed 2021-11-10 | |
| 2020-03-31 | -$19.59M 10-Q · filed 2021-11-10 | -$34.38M derived: sum of 2 quarters · filed 2021-11-10 | -$47.30M derived: sum of 3 quarters · filed 2021-11-10 | -$61.09M derived: sum of 4 quarters · filed 2021-11-10 | |
| 2019-12-31 | -$14.79M 10-K · filed 2021-03-18 | -$27.70M derived: sum of 2 quarters · filed 2021-03-18 | -$41.49M derived: sum of 3 quarters · filed 2021-03-18 | -$119.20M 10-K · filed 2023-03-30 | -$55.74M 10-K · filed 2020-03-16 |
| 2019-09-30 | -$12.91M 10-K · filed 2021-03-18 | -$26.70M derived: sum of 2 quarters · filed 2021-03-18 | -$40.95M 10-Q · filed 2020-11-05 | -$42.45M derived: sum of 4 quarters · filed 2021-03-18 | |
| 2019-06-30 | -$13.79M 10-K · filed 2021-03-18 | -$28.04M 10-Q · filed 2020-08-06 | -$29.54M derived: sum of 3 quarters · filed 2021-03-18 | -$39.77M derived: sum of 4 quarters · filed 2021-03-18 | |
| 2019-03-31 | -$14.25M 10-K · filed 2021-03-18 | -$15.74M derived: sum of 2 quarters · filed 2021-03-18 | -$25.98M derived: sum of 3 quarters · filed 2021-03-18 | -$37.52M derived: sum of 4 quarters · filed 2021-03-18 | |
| 2018-12-31 | -$1.49M 10-K · filed 2020-03-16 | -$11.73M derived: sum of 2 quarters · filed 2020-03-16 | -$23.27M derived: sum of 3 quarters · filed 2020-03-16 | -$35.32M 10-K · filed 2021-03-18 | |
| 2018-09-30 | -$10.24M 10-K · filed 2020-03-16 | -$21.78M derived: sum of 2 quarters · filed 2020-03-16 | -$33.82M 10-Q · filed 2019-11-08 | -$49.17M derived: sum of 4 quarters · filed 2020-03-16 | |
| 2018-06-30 | -$11.54M 10-K · filed 2020-03-16 | -$23.59M 10-Q · filed 2019-08-14 | -$38.93M derived: sum of 3 quarters · filed 2020-03-16 | -$40.35M derived: sum of 4 quarters · filed 2020-03-16 | |
| 2018-03-31 | -$12.05M 10-K · filed 2020-03-16 | -$27.39M derived: sum of 2 quarters · filed 2020-03-16 | -$28.81M derived: sum of 3 quarters · filed 2020-03-16 | -$30.62M derived: sum of 4 quarters · filed 2020-03-16 | |
| 2017-12-31 | -$15.34M 10-K · filed 2019-04-01 | -$16.76M derived: sum of 2 quarters · filed 2019-04-01 | -$18.57M derived: sum of 3 quarters · filed 2019-04-01 | -$19.69M 10-K · filed 2020-03-16 | |
| 2017-09-30 | -$1.42M 10-K · filed 2019-04-01 | -$3.23M derived: sum of 2 quarters · filed 2019-04-01 | -$4.34M 10-Q · filed 2018-11-14 | ||
| 2017-06-30 | -$1.81M 10-K · filed 2019-04-01 | -$2.93M derived: sum of 2 quarters · filed 2019-04-01 | |||
| 2017-03-31 | -$1.11M 10-K · filed 2019-04-01 | ||||
| 2016-12-31 | $1.70M 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |